Xenon MRI in Stable Pulmonary Hypertension (Jupiter AUGEAN)

Pulmonary Artery Hypertension Clinical Trial

Official title:

Xenon MRI in Stable Patients With Pulmonary Hypertension

Clinical Trial Details — Status: Withdrawn

Administrative data

• NCT number: NCT06122922
• Other study ID #: Pro00113235
• Status: Withdrawn
• Phase: Phase 2
• Start date: March 15, 2024
• Est. completion date: December 31, 2025

Study information

• Verified date: January 2024
• Source: Duke University
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The objective of this project is to determine how pulmonary vascular remodeling in Pulmonary Arterial Hypertension (PAH) at cellular and pathological level is associated with gas exchange physiology changes and hemodynamics (monitored with 129Xe MRI/MRS) and how these signals change with disease progression or treatment.

Description:

The clinical and research need for noninvasive biomarkers in pulmonary arterial hypertension (PAH) has led the study team to develop 129Xe magnetic resonance imaging (129Xe MRI) to image pulmonary vascular pathology through quantitative 3D maps of gas transfer across the pulmonary blood-gas barrier. 129Xe MRI, in combination with 129Xe spectroscopy (MRS), has a unique signature in PAH and can simultaneously measure capillary blood volume and hemodynamic changes associated with pulmonary vascular remodeling (Wang '19a). This project aims to determine how pulmonary vascular remodeling in PAH at a cellular and pathological level is related to gas exchange physiology changes and hemodynamics (monitored with 129Xe MRI/MRS) and the change in these signals over one year in patients with "stable" PAH. Our central hypothesis is that patients with "stable" PAH will display persistent abnormalities on 129Xe MRI/MRS consistent with pulmonary vascular remodeling and that some patients may have worsening of their disease while appearing to be "stable" disease. The study team will assess the ability of 129Xe MRI to longitudinally monitor disease progression in patients with "stable" PAH. First, the team will enroll "stable" PAH patients and obtain detailed clinical information to be stored in the REDCAP database. The study team will then follow this cohort of PAH subjects for one year, performing 129Xe MRI scans at baseline, 3 months, 6 months and one year in addition to their standard-of-care assessments including appointments labs, echo, and 6MWTs.

Recruitment information / eligibility

• Status: Withdrawn
• Enrollment: 0
• Est. completion date: December 31, 2025
• Est. primary completion date: December 31, 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria:

1. Stable on current treatment regimen and not planning to undergo initiation of new therapy for at least 3 months

2. Outpatients of any gender, Age 18-75

3. WHO functional class (FC) 1-3 symptoms with a diagnosis of group 1 PH (mean pulmonary artery pressures (mPAP) > 20 mmHg, pulmonary capillary wedge pressure (PCWP) = 15mmHg and pulmonary vascular resistance (PVR) =3 WU)

4. Willing and able to give informed consent and adhere to visit/protocol schedules (consent must be given before any study procedures are performed).

5. Women of childbearing potential must have a negative urine pregnancy test before MRI

Exclusion Criteria:

6. Sarcoidosis

7. Active cancer

8. Sickle cell anemia

9. Liver disease (Childs-Pugh class C)

10. Any conditions that prevent the performance of 129Xe MRI scans.

11. Prisoners and pregnant women will not be approached for the study

12. Conditions that will prohibit MRI scanning (metal in eye, claustrophobia, inability to lie supine)

13. Medical or psychological conditions which, in the opinion of the investigator, might create undue risk to the subject or interfere with the subject's ability to comply with the protocol requirements

Related Conditions & MeSH terms

• Hypertension
• Hypertension, Pulmonary
• Pulmonary Arterial Hypertension
• Pulmonary Artery Hypertension

Intervention

Drug:
• Hyperpolarized Xe129
Hyperpolarized Xenon Gas

Locations

Country	Name	City	State
n/a

Sponsors (2)

Lead Sponsor	Collaborator
Bastiaan Driehuys	Regeneron Pharmaceuticals

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change in pulmonary vascular function	Measured by RBC/Membrane metrics on Xe MRI	Baseline, 3 months, 6 months, 1 year
Primary	Change in pulmonary vascular function	Measured by RBC shift metrics on Xe MRI	Baseline, 3 months, 6 months, 1 year
Primary	Change in pulmonary vascular functoin	Measured by RBC amplitude oscillation metrics on Xe MRI	Baseline, 3 months, 6 months, 1 year
Secondary	Six Minute Walk Test Distance (6MWD)	Distance patient is able to walk during a six minute walk test	Baseline, 3 months, 6 months, 1 year
Secondary	NTproBNP	Lab value of NTproBNP	Baseline, 3 months, 6 months, 1 year
Secondary	World Health Organization (WHO) Functional Class (FC)	Change in Functional Class of Pulmonary Hypertension symptoms	Baseline, 3 months, 6 months, 1 year
Secondary	Hopsitalizations	Frequency of hospitalizations	Baseline, 3 months, 6 months, 1 year